NSTM_IR

NovelStem International IR

NovelStem Owns ~30% of NewStem, Israel-based developer of stem cell-based diagnostic platform to identify resistance to cancer treatments, prior to treatment.

Strategy:
EquitiesGrowthProfessional
Joined Feb 2022

Advertisement|Remove ads.

Advertisement|Remove ads.

Advertisement|Remove ads.